Orphazyme A/S: Election of new members of the Board of Directors
|Company announcement||Orphazyme A/S|
|No. 4/2017||Ole Maaløes Vej 3|
|DK-2200 Copenhagen N|
|Company Registration No. 32266355|
|16 November 2017|
On 16 November 2017, Orphazyme A/S ("Orphazyme") held an extraordinary general meeting at which Anders Hedegaard and Catherine Moukheibir were elected as new members of the Board of Directors as set out in the offering circular (the "Offering Circular") published on 6 November 2017 in connection with the Initial Public Offering and admission to trading and official listing of Orphazyme on Nasdaq Copenhagen A/S.
Anders Hedegaard is currently chief executive officer of GN Store Nord A/S and GN Hearing A/S and was previously CEO of Bavarian Nordic A/S. Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.
Catherine Moukheibir is currently chairman of the board of directors of MedDay Pharmaceuticals SA, member of the board of directors of Zealand Pharma A/S (publ) and Genkyotex SA (publ), as well as a member of the board of directors of Ablynx NV (publ) and Cerenis Therapeutics SA (publ). Catherine Moukheibir holds a Master in Economics and an MBA degree, both from Yale University.
As described in the Offering Circular, Martin Rahbek Kornum, Nanna Lüneborg and Patrick Krol resigned from the Board of Directors in connection with the extraordinary general meeting.
The Board of Directors is now composed as follows:
|Composition of board committees|
|Name||Position||Audit committee||Remuneration committee||Nomination committee|
|Bo Jesper Hansen||Deputy Chairman||Chair|
All members of the Board of Directors are considered independent for purposes of the current Danish Corporate Governance Recommendations.
|For additional information, please contact|
|Anders Vadsholt, CFO||+45 28 98 90 55|
Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. The Company was founded in 2009 based on early scientific discovery in heat shock proteins ("HSPs"). Since inception, the Company has translated scientific discovery into a late stage clinical development programme. The Company is headquartered in Copenhagen and currently has 30 employees.
The Company focuses on severe and mostly fatal diseases with a high unmet need, and with a particularly strong commitment to neuromuscular diseases and a group of severe genetic diseases called lysosomal storage diseases. The Company plans to pursue development of its lead candidate through to registration in the EU and the United States after which launch and commercialisation is expected to be undertaken by the Company.
The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis ("sIBM") and Amyotrophic Lateral Sclerosis ("ALS"), and two lysosomal storage diseases, Niemann Pick type C ("NPC") and Gaucher disease.